Phase 2 N=108 Citalopram for Cocaine Dependence
Cocaine Dependence
Primary: Number of Participants Who Are Cocaine Abstinent During the Last 2 Weeks of Treatment (Weeks 8-9), as Assessed by Urine Test — 0; 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=47 Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
Treatment of Depression in Adults With Parkinson's Disease (PD)
Primary: Change From Baseline to Week 8 in HAMD-17 (Hamilton Depression Scale -17 Items) Total Score — 19.2; 8.1 score on a scale — p=<0.0001
Phase 2 N=309 A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32 — 95; 94; 91…
Phase 2 N=73 A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 9; 9; 15 participants
Phase 2 N=14 Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious Adverse Events (SAEs) — 14; 5; 8; 1 Participants
Phase 2 N=50 Trial of Curcumin in Advanced Pancreatic Cancer
Pancreatic Neoplasms · Adenocarcinoma
Primary: Six-Month Participant Survival — 7 Participants
Phase 2 N=30 Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration
Wet Age-related Macular Degeneration
Primary: Best Corrected Visual Acuity (BCVA) — 7.0 letters
Phase 2 N=26 Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
Wet Age-related Macular Degeneration
Primary: Best Corrected Visual Acuity (BCVA) — 2.0 letters
Phase 2 N=97 Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin
Vaginitis Gardnerella
Primary: The Proportion of Participants With Eradication of Gardnerella Vaginalis (GV) in Each Study Arm at Visit 2 (Day 15-21) as Assessed by Nucleic Acid Amplification Test…
Phase 2 N=150 Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Week 2 — 18; 18; 3; 1…
Phase 2 N=117 A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 — -5.12; -5.94; -5.02; -5.25 mmHg (milimeters of mercury)
Phase 2 N=18 A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
Prostate Cancer
Primary: Number of Lesions With Gleason Score ≥ 7 Identified by Ultrasound Molecular Imaging — 17; 8 number of lesions
Phase 2 N=176 Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Primary Open Angle Glaucoma · Ocular Hypertension · Pigmentary Glaucoma
Primary: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 — -6.96; -7.09; -8.20; -6.02 mmHg (milimeters of mercury)
Phase 2 N=24 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Brain Cancer · Pediatric Cancers
Primary: Objective Response Rate — 0 Percentage of Participants
Phase 2 N=42 Buproprion for Binge Drinking
Alcohol Abuse
Primary: Change in Proportion of Binge Drinking Days — -0.13; -0.11 Binge Drinking Days